Companies
Akili Interactive
received FDA authorization for EndeavorOTC in June 2024, the first FDA clearance of a digital treatment for adult ADHD delivered through a video game, and launched ENDEAVORRIDE in Japan with Shionogi in June 2026 as the first adjunctive therapy app for pediatric ADHD in that market.
- Country
- United States
- Ticker
- AKLI
FDA cleared
ADHD treatment
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $383,000 for the three months ended March 31, 2024 (2024-03-31) | sec.gov |
| Revenue | $1.7 million for full year 2023 (2023-12-31) | businesswire.com |
| Regulatory approval | FDA clearance for EndeavorOTC (AKL-T01) as an over-the-counter treatment for adults with ADHD (2024-06-18) | businesswire.com |
| Regulatory approval | FDA clearance for EndeavorRx (AKL-T01) as a prescription treatment for children with ADHD (2020-06-15) | akiliinteractive.com |
| Headquarters | Boston, Massachusetts (2022-07-31) | content.edgar-online.com |
Independent sources: businesswire.com · content.edgar-online.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Digital therapeutics | regenerative-personalized | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.